UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 9, 2026 (June 05, 2026)
ADAPTIVE BIOTECHNOLOGIES CORPORATION
(Exact name of Registrant as Specified in Its Charter)
Washington
001-38957
27-0907024
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1165 Eastlake Avenue East
Seattle, Washington
98109
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code:(206)659-0067
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share
ADPT
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 5, 2026, Adaptive Biotechnologies Corporation (the "Company") held its annual meeting of shareholders (the "Annual Meeting") pursuant to notice duly given. Three proposals were presented for voting: Proposal 1: election of two Class I directors to the Board of Directors (Robert Hershberg, PhD, MD and Katey Owen, PhD); Proposal 2: an advisory request concerning compensation for the Company's 2025 named executive officers; and, Proposal 3: ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. Each of the proposals was described in detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026. A quorum of the shareholders voted by the conclusion of the Annual Meeting. The final results of the voting are set forth below.
Proposal 1: Election of Two Class I Directors
Robert Hershberg PhD, MD
Votes Submitted
As % of Proposal Votes
Broker Non Vote
For
93,188,652
71.81 %
13,570,859
Against
-
-
Withhold/Abstain
36,573,708
28.19 %
Katey Owen, PhD
Votes Submitted
As % of Proposal Votes
Broker Non Vote
For
126,803,695
97.72 %
13,570,859
Against
-
-
Withhold/Abstain
2,958,666
2.28 %
Proposal 2: Advisory Vote Concerning the 2025 Compensation of the Company's Named Executive Officers
Votes Submitted
As % of Proposal Votes
Broker Non Vote
For
125,287,618
96.55 %
13,570,859
Against
4,316,144
3.33 %
Withhold/Abstain
158,599
0.12 %
Proposal 3: Ramification of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Year Ending December 31, 2026
Votes Submitted
As % of Proposal Votes
Broker Non Vote
For
142,609,643
99.50 %
0
Against
484,798
0.34 %
Withhold/Abstain
238,779
0.17 %
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.